Johnson & Johnson delivered solid earnings that exceeded analyst expectations, particularly in adjusted EPS despite a slight decline in sales. Management provided a confident outlook with continued investment in innovation and strategic growth, which should support the stock in the short term despite currency headwinds.

[1]